The Effect of Contralateral Prophylactic Mastectomy on Perioperative Complications in Women Undergoing Immediate Breast Reconstruction: A NSQIP Analysis
Overview
Affiliations
Background: Women with breast cancer are increasingly choosing to undergo contralateral prophylactic mastectomy (CPM) despite questionable survival benefit and limited data on added risks. Little is known about differences in perioperative complications between women who undergo bilateral mastectomy (BM) versus unilateral mastectomy (UM) with reconstruction.
Methods: The American College of Surgeons National Surgery Quality Improvement Program Participant Use Files (2005-2013) were used to identify women with unilateral breast cancer who underwent UM or BM with reconstruction. Adjusted 30-day complications were compared between UM and BM groups using logistic regression models.
Results: A total of 20,501 patients were identified, of whom 35.3 % underwent BM. Of these, 84.3 % had implant reconstruction and 15.7 % had autologous reconstruction. For all women, BM was associated with longer hospital stays (adjusted odds ratio [aOR] 1.98-2.09, p < 0.001) and a higher transfusion rate than UM (aOR 2.52-3.06, p < 0.001). BM with implant reconstruction was associated with a modestly increased reoperation rate (aOR 1.15, p = 0.029). BM with autologous reconstruction was associated with a higher wound disruption rate (aOR 2.51, p = 0.015). Surgical site infections, prosthesis failure, and medical complications occurred at similar rates in UM and BM groups.
Conclusions: CPM is associated with significant increases in some, but not all, surgical site complications. CPM does not increase the likelihood of medical complications, which are generally infrequent.
Singh P, Agnese D, Amin M, Barrio A, van den Bruele A, Burke E Ann Surg Oncol. 2024; 31(4):2212-2223.
PMID: 38261126 DOI: 10.1245/s10434-024-14893-x.
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
Schmidt M, Kelly J, Bredart A, Cameron D, de Boniface J, Easton D Eur J Cancer. 2023; 181:79-91.
PMID: 36641897 PMC: 10326619. DOI: 10.1016/j.ejca.2022.11.036.
Briceno-Morales X, Briceno-Morales C, Guerrero-Macias S, Pedroza-Duran A, Suarez-Rodriguez R Rev Colomb Obstet Ginecol. 2021; 72(3):307-318.
PMID: 34851573 PMC: 8603825. DOI: 10.18597/rcog.3690.
Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z Cancer Cell Int. 2021; 21(1):512.
PMID: 34563200 PMC: 8466340. DOI: 10.1186/s12935-021-02194-2.
Deliere A, Attai D, Victorson D, Kuchta K, Pesce C, Kopkash K Ann Surg Oncol. 2021; 28(10):5686-5697.
PMID: 34432189 DOI: 10.1245/s10434-021-10452-w.